Dasatinib-Induced Chylothorax: A Clinical Laboratory’s Perspective

Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez, Rafael J. García, Gea, Clara Sanz, Martin-Riera, Víctor, Ruiz, Armando Raúl Guerra, Barzanti, Rosanna Paciucci, Ferrer-Costa, Roser, Ramirez-Serra, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Communications and Publications Division (CPD) of the IFCC 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131239/
https://www.ncbi.nlm.nih.gov/pubmed/37124659
Descripción
Sumario:Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis of the pleural effusion is crucial for chylothorax diagnosis. We report a case of a 53-year-old male patient presenting a chylothorax after 14 years of dasatinib therapy where the clinical laboratory was key in the diagnosis.

Ejemplares similares